These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 32603434)

  • 1. Validation of Fibroblast Growth Factor 23 Assays.
    Jialal I
    J Appl Lab Med; 2020 Jul; 5(4):819-821. PubMed ID: 32603434
    [No Abstract]   [Full Text] [Related]  

  • 2. GFR-Specific versus GFR-Agnostic Cutoffs for Parathyroid Hormone and Fibroblast Growth Factor-23 in Advanced Chronic Kidney Disease.
    Canney M; Djurdjev O; Tang M; Zierold C; Blocki F; Wolf M; Levin A
    Am J Nephrol; 2019; 50(2):105-114. PubMed ID: 31238301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of fractional phosphate excretion on the relation of FGF23 with outcome in CKD patients.
    Bech AP; Bouma-de Krijger A; van Zuilen AD; Bots ML; van den Brand JA; Blankestijn PJ; Wetzels JF; Vervloet MG
    J Nephrol; 2015 Aug; 28(4):477-84. PubMed ID: 25700931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical prediction models for progression of chronic kidney disease to end-stage kidney failure under pre-dialysis nephrology care: results from the Chronic Kidney Disease Japan Cohort Study.
    Hasegawa T; Sakamaki K; Koiwa F; Akizawa T; Hishida A;
    Clin Exp Nephrol; 2019 Feb; 23(2):189-198. PubMed ID: 30069609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma Klotho is not related to kidney function and does not predict adverse outcome in patients with chronic kidney disease.
    Seiler S; Wen M; Roth HJ; Fehrenz M; Flügge F; Herath E; Weihrauch A; Fliser D; Heine GH
    Kidney Int; 2013 Jan; 83(1):121-8. PubMed ID: 22895520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathophysiological impact of serum fibroblast growth factor 23 in patients with nonischemic cardiac disease and early chronic kidney disease.
    Imazu M; Takahama H; Asanuma H; Funada A; Sugano Y; Ohara T; Hasegawa T; Asakura M; Kanzaki H; Anzai T; Kitakaze M
    Am J Physiol Heart Circ Physiol; 2014 Nov; 307(10):H1504-11. PubMed ID: 25217649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibroblast growth factor 23 and new-onset chronic kidney disease in the general population: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study.
    De Jong MA; Eisenga MF; van Ballegooijen AJ; Beulens JWJ; Vervloet MG; Navis G; Gansevoort RT; Bakker SJL; De Borst MH
    Nephrol Dial Transplant; 2021 Jan; 36(1):121-128. PubMed ID: 32124925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibroblast Growth Factor 23 and Risk of CKD Progression in Children.
    Portale AA; Wolf MS; Messinger S; Perwad F; Jüppner H; Warady BA; Furth SL; Salusky IB
    Clin J Am Soc Nephrol; 2016 Nov; 11(11):1989-1998. PubMed ID: 27561289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibroblast growth factor 23 and incident CKD in type 2 diabetes.
    Isakova T; Craven TE; Lee J; Scialla JJ; Xie H; Wahl P; Marcovina SM; Byington RP; Wolf M
    Clin J Am Soc Nephrol; 2015 Jan; 10(1):29-38. PubMed ID: 25343949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FGF-23 and Osteoprotegerin but not Fetuin-A are associated with death and enhance risk prediction in non-dialysis chronic kidney disease stages 3-5.
    Alderson HV; Ritchie JP; Middleton R; Larsson A; Larsson TE; Kalra PA
    Nephrology (Carlton); 2016 Jul; 21(7):566-73. PubMed ID: 27334353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FGF23 and Left Ventricular Hypertrophy in Children with CKD.
    Mitsnefes MM; Betoko A; Schneider MF; Salusky IB; Wolf MS; Jüppner H; Warady BA; Furth SL; Portale AA
    Clin J Am Soc Nephrol; 2018 Jan; 13(1):45-52. PubMed ID: 29025789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serial Fibroblast Growth Factor 23 Measurements and Risk of Requirement for Kidney Replacement Therapy: The CRIC (Chronic Renal Insufficiency Cohort) Study.
    Mehta R; Cai X; Lee J; Xie D; Wang X; Scialla J; Anderson AH; Taliercio J; Dobre M; Chen J; Fischer M; Leonard M; Lash J; Hsu CY; de Boer IH; Feldman HI; Wolf M; Isakova T;
    Am J Kidney Dis; 2020 Jun; 75(6):908-918. PubMed ID: 31864822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of inflammation by acute sepsis on intact fibroblast growth factor 23 (iFGF23) and asymmetric dimethyl arginine (ADMA) in CKD patients.
    Dounousi E; Torino C; Pizzini P; Cutrupi S; Panuccio V; D'Arrigo G; Abd ElHafeez S; Tripepi G; Mallamaci F; Zoccali C
    Nutr Metab Cardiovasc Dis; 2016 Jan; 26(1):80-3. PubMed ID: 26712271
    [No Abstract]   [Full Text] [Related]  

  • 14. Single Measurements of Carboxy-Terminal Fibroblast Growth Factor 23 and Clinical Risk Prediction of Adverse Outcomes in CKD.
    Edmonston D; Wojdyla D; Mehta R; Cai X; Lora C; Cohen D; Townsend RR; He J; Go AS; Kusek J; Weir MR; Isakova T; Pencina M; Wolf M;
    Am J Kidney Dis; 2019 Dec; 74(6):771-781. PubMed ID: 31445926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease.
    Munoz Mendoza J; Isakova T; Cai X; Bayes LY; Faul C; Scialla JJ; Lash JP; Chen J; He J; Navaneethan S; Negrea L; Rosas SE; Kretzler M; Nessel L; Xie D; Anderson AH; Raj DS; Wolf M;
    Kidney Int; 2017 Mar; 91(3):711-719. PubMed ID: 28017325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphate, fibroblast growth factor 23 and retinopathy in chronic kidney disease: the Chronic Renal Insufficiency Cohort Study.
    Mehta R; Ying GS; Houston S; Isakova T; Nessel L; Ojo A; Go A; Lash J; Kusek J; Grunwald J; Wolf M;
    Nephrol Dial Transplant; 2015 Sep; 30(9):1534-41. PubMed ID: 25910495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Role of the morphogenetic proteins FGF-23 and Klotho and the glycoprotein sclerostin in the assessment of the risk of cardiovascular diseases and the prognosis of chronic kidney disease].
    Milovanova LY; Milovanov YS; Kudryavtseva DV; Markina MM; Milovanova SY; Kozlovskaya LV; Lebedeva MV; Beketov VD; Moiseev SV; Mukhin NA; Fomin VV; Svistunov AA
    Ter Arkh; 2015; 87(6):10-16. PubMed ID: 26281189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibroblast Growth Factor 23 and α-Klotho Protein Are Associated with Adverse Clinical Outcomes in Non-Dialysis CKD Patients.
    Manou E; Thodis E; Arsos G; Pasadakis P; Panagoutsos S; Papadopoulou D; Papagianni A
    Kidney Blood Press Res; 2020; 45(6):900-915. PubMed ID: 33040068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibroblast Growth Factor 23 and Anemia in the Chronic Renal Insufficiency Cohort Study.
    Mehta R; Cai X; Hodakowski A; Lee J; Leonard M; Ricardo A; Chen J; Hamm L; Sondheimer J; Dobre M; David V; Yang W; Go A; Kusek JW; Feldman H; Wolf M; Isakova T;
    Clin J Am Soc Nephrol; 2017 Nov; 12(11):1795-1803. PubMed ID: 28784656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined use of vitamin D status and FGF23 for risk stratification of renal outcome.
    Nakano C; Hamano T; Fujii N; Matsui I; Tomida K; Mikami S; Inoue K; Obi Y; Okada N; Tsubakihara Y; Isaka Y; Rakugi H
    Clin J Am Soc Nephrol; 2012 May; 7(5):810-9. PubMed ID: 22362065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.